The information contained on this site is intended for institutional investors only, and is published strictly for informational purposes only without regard to the investment objective, financial situation or specific needs of any particular investor. The information is not intended for use by institutional investors in a jurisdiction where distribution or purchase is not authorized.
An institutional investor is one that falls within one or more of the following categories:
If you do not fall within at least one of the above categories you should not access the information contained in the site.
Baron Capital Management, Inc. makes reasonable efforts to ensure the material on the site is as accurate and timely as possible and that disruptions of service are minimal, Baron Capital Management, Inc. makes no warranty or guarantee concerning the availability of this site or the services or the accuracy of the information on it. In addition, the information contained on the site is in no way intended to constitute investment advice, an offer to sell, or a recommendation of any security or investment product. In fact, the products described herein may not be available to, or suitable for, all investors. You should consider, if appropriate, obtaining independent professional advice before making an investment decision. Please consider the charges, risks, expenses and investment objectives carefully before investing. Nothing on this site is intended to constitute legal or tax advice.
Please keep in mind that the opinions and views expressed through the content and commentaries published on the site are just that - opinions and views - and that they are published on the site for informational purposes only. In addition, views and opinions are based on the information available at the time and may not necessarily be shared by Baron Capital Management, Inc., or its employees, in general. As the investing environment changes, so could this information, and Baron Capital Management, Inc. has no responsibility to update it.
Past performance is not a guarantee of future performance. Investment results and principal value will fluctuate so shares, when redeemed, may be worth more or less than their original cost. Investors should be aware of the additional risks associated with investments in non-diversification, undervalued or overlooked companies and investments in specific industries. Additional risks may include those associated with investing in foreign securities, emerging markets, and companies with relatively small market capitalizations.
By selecting “I Agree” below, you confirm that you are an institutional investor or consultant to an institutional investor.
Baron offers accredited non-U.S. investors and qualified tax-exempt U.S. investors a range of options for investing in the equity market. Our investment vehicles include SICAV funds, separate accounts, collective investment trusts, and Baron USA Partners Fund.
This website may not be suitable for everyone, and if you are at all unsure whether an investment product referenced on this website will meet your individual needs, please seek professional advice before proceeding further with such product. Nothing on this website is, or is intended to be, an offer, advice, or an invitation to buy or sell any investments, in any jurisdiction where, or to anyone whom it would be unlawful to do so. By clicking “I Agree” below you acknowledge that you have read and understood this important information. Information on this website is issued by Baron Capital, Inc.
For any queries or questions coming from EU/EEA potential investors, please contact Arnaud Gérard, CFA, Managing Director FundRock Distribution at Arnaud.GERARD@Fundrock.com or call +352691992088.
For information on Baron Capital or any queries or questions coming from non-EU/EEA potential investors, please contact Stephen Millar, VP, Head of EMEA Institutional Sales at firstname.lastname@example.org or call +44(0)7769-958822.
By selecting “I Agree” below, you confirm that you are an accredited non-U.S. investor or a qualified tax-exempt U.S. investor.
The link you have selected is not available within the Institution user experience. You will be switched to view this website as a Financial Advisor.
When you wish to view strategies again, click an 'Institution' link within the 'View As' menu or 'Strategies' in the footer.
Thank you for your email. We will respond as soon as possible.
as of 09/30/23
One of the biggest growth categories in health care today is the use of GLP-1 medicines to treat type 2 diabetes and obesity. Although GLP-1s have been used to treat diabetes for many years, the newest generation (Ozempic, Wegovy, Mounjaro) are more effective and can also help people lose 15% or more of their body weight. The August news of Novo Nordisk’s SELECT trial results showed that these newer GLP-1s also benefit cardiovascular health. This news sent shockwaves through the market as investors digested the potential impact of GLP-1s on health care companies, food and beverage manufacturers, restaurants, retailers, and even tobacco and gaming companies.
Elsewhere within the sector, multiple headwinds weighed on performance. Managed care companies continued to grapple with heightened political and regulatory scrutiny of the Medicare Advantage program and the pharmacy benefit management industry, less favorable Medicare Advantage rates for 2024, and an uptick in medical cost trends. The challenging funding environment for biotech continued. Life sciences tools stocks were impacted by a pullback in spending by pharmaceutical customers, less biotech funding, a slowdown in China, and inventory destocking.
The Center for Medicare and Medicaid Services released the list of the first 10 drugs to be subject to price negotiation under the Inflation Reduction Act. The list did not surprise investors, and many of the drugs will be close to patent expiration by the time they are subject to negotiation. We are tracking litigation challenging the program’s constitutionality and monitoring whether and how it will impact biopharmaceutical R&D spend.
Against this backdrop, Baron Health Care Fund declined. Holdings within the pharmaceuticals, managed health care, and biotechnology sub-industries contributed the most. Investments within the health care equipment, life sciences tools & services, and health care supplies sub-industries detracted the most. Top contributor Eli Lilly and Company led gains within pharmaceuticals. Third largest contributor UnitedHealth Group Incorporated drove positive returns within managed health care. Appreciation within biotechnology was led by second largest contributor argenx SE. Health care equipment had a weak quarter, with top detractor Inspire Medical Systems, Inc. and second largest detractor DexCom, Inc. both within the sub-industry. Third largest detractor Exact Sciences Corporation led declines within life sciences tools & services. Both positions within health care supplies lost ground.
Despite a multitude of near-term headwinds, our long-term outlook for Health Care remains bullish. Innovation in the sector and the themes in which we have been investing are intact. We believe the portfolio includes competitively advantaged growth companies with pricing power, strong management, and excellent balance sheets.
as of 09/30/23
as of 09/30/23
When reviewing performance attribution on our portfolio, please be aware that we construct the portfolio from the bottom up, one stock at a time. Each stock is included in the portfolio if it meets our rigorous investment criteria. To help manage risk, we are aware of our sector and security weights, but we do not include a holding to achieve a target sector allocation or to approximate an index. Our exposure to any given sector is purely a result of our stock selection process.
as of 09/30/23
Baron Health Care Fund (Institutional Shares) was down 6.05% in the third quarter, trailing the Russell 3000 Health Care Index by 217 basis points due to a combination of stock selection and active sub-industry weights.
Investments in health care equipment, life sciences tools & services, biotechnology, and health care supplies accounted for most of the underperformance in the period. Adverse stock selection in health care equipment was linked to concerns about growing adoption of Wegovy, Ozempic, Mounjaro, and other GLP-1 drugs and how it will impact the growth prospects of certain Fund holdings, namely sleep apnea treatment leader Inspire Medical Systems, Inc. and diabetes device companies DexCom, Inc. and Insulet Corporation. Novo Nordisk released SELECT trial results in early August showing that Wegovy reduced major adverse cardiovascular events by 20% in overweight adults aged 45 or older with cardiovascular disease and no prior history of diabetes. With the study’s results supporting broader insurance coverage of GLP-1 drugs, some investors believe increased GLP-1 adoption will potentially shrink the size of Inspire Medical's addressable market and the terminal value of the stock because weight loss could reduce the severity of sleep apnea. Similarly, there are investors who think increased use of GLP-1 drugs may slow the progression of diabetes and lead to less insulin and continuous glucose monitoring use. We retain conviction and offer additional detail on these holdings in our quarterly letter.
Weakness in life sciences tools & services was driven by double-digit declines from cancer diagnostics company Exact Sciences Corporation and precision instruments provider Mettler-Toledo International Inc. After rallying in the first half of the year as competition-related concerns from liquid biopsy dissipated, Exact Sciences’ shares pulled back. The company reported solid quarterly results that fell short of lofty expectations. There is also more potential liquid biopsy data coming (such as from privately held Freenome), which we believe also served as an overhang. The screening market for colon cancer is vast, however, and management continues to build optionality by moving several liquid biopsy programs of their own through the pipeline. Mettler’s stock declined in response to disappointing second quarter financial results and lowered 2023 guidance. Management noted market conditions in China have worsened considerably, particularly among biopharmaceutical customers who are delaying investment decisions as they wait for government stimulus. Management also stated that global manufacturing PMIs have continued to trend lower. We think these headwinds are temporary and continue to believe Mettler has a solid long-term outlook. Another material detractor in the sub-industry was Bio-Techne Corporation, a leading developer and manufacturer of reagents, instruments, and services for the life sciences research, diagnostics, and bioprocessing markets. Bio-Techne’s shares were pressured by various headwinds in the life sciences tools end market including reduced biotechnology funding, continued inventory destocking by customers, and a slowdown in China.
The relative shortfall in biotechnology mostly had to do with owning a few larger cap names, particularly AbbVie Inc., Amgen Inc., and Regeneron Pharmaceuticals, Inc., whose share prices were up double digits for the quarter as investors flocked to larger, safer, cash flow positive biotechnology companies as long-term interest rates rose. These losses were somewhat blunted by gains from the Fund’s sizeable positions in argenx SE and Rocket Pharmaceuticals, Inc. The Fund’s higher exposure to heath care supplies via positions in The Cooper Companies, Inc. and Neogen Corp. also proved costly as the sub-industry was among the worst performers in the index during the quarter.
Partially offsetting the above was favorable stock selection in pharmaceuticals and health care distributors along with cash exposure in a declining market. Strength in pharmaceuticals and health care distributors was driven by gains from Eli Lilly and Company and McKesson Corporation, respectively. Global pharmaceutical company Lilly was the largest contributor due to strong second quarter sales of Mounjaro and ongoing enthusiasm surrounding the company’s obesity and diabetes franchises. McKesson is a leading distributor of pharmaceuticals and medical supplies and also provides prescription technology solutions that connect pharmacies, providers, payers, and biopharmaceutical customers. McKesson’s stock performed well due to strong financial results in the company’s pharmaceutical distribution and prescription technology solutions businesses, driven in part by higher volumes of GLP-1 medicines and prior authorization technology services related to GLP-1 medicines.
Investors should consider the investment objectives, risks, and charges and expenses of the investment carefully before investing. The prospectus and summary prospectuses contain this and other information about the Funds. You may obtain them from the Funds’ distributor, Baron Capital, Inc., by calling 1-800-99BARON or visiting www.BaronFunds.com. Please read them carefully before investing.
The performance data quoted represents past performance. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate; an investor's shares, when redeemed, may be worth more or less than their original cost. The Fund’s transfer agency expenses may be reduced by expense offsets from an unaffiliated transfer agent, without which performance would have been lower. Current performance may be lower or higher than the performance data quoted.
Risks:All investments are subject to risk and may lose value.
The discussion of market trends is not intended as advice to any person regarding the advisability of investing in any particular security. The views expressed on this page reflect those of the respective writer. Some of our comments are based on management expectations and are considered “forward-looking statements.” Actual future results, however, may prove to be different from our expectations. Our views are a reflection of our best judgment at the time and are subject to change at any time based on market and other conditions and Baron has no obligation to update them
Portfolio holdings are subject to change. Current and future portfolio holdings are subject to risk.
The index performance is not fund performance; one cannot invest directly into an index.